Financial Data and Key Metrics Changes - In 2025, ANI Pharmaceuticals achieved record revenues of $883.4 million, representing a 44% year-over-year increase [12][44] - Adjusted non-GAAP EBITDA for the full year was $229.8 million, up 47% compared to the previous year [54] - Adjusted non-GAAP diluted EPS for 2025 was $7.89, compared to $5.20 in 2024 [53] Business Line Data and Key Metrics Changes - Revenues from Cortrophin Gel reached $347.8 million for the full year, a 76% increase year-over-year [45] - The generics business generated $384.1 million in revenue for 2025, also reflecting a 28% year-over-year growth [46] - ILUVIEN net revenues were $74.9 million for the full year, with fourth-quarter revenues of $19.8 million [45] Market Data and Key Metrics Changes - The ACTH market approached $1 billion in sales in 2025 and is expected to grow significantly in 2026, with Cortrophin Gel projected to grow by 55% to 65% [27] - Approximately 10 million patients in the U.S. suffer from gouty arthritis, with only about 36% receiving treatment annually [28] Company Strategy and Development Direction - ANI's strategic priorities for 2026 include transforming into a leading rare disease company, executing in the generics business, and maintaining disciplined capital allocation [14][19] - The company plans to expand its dedicated organization for acute gouty arthritis flares to capture additional market opportunities [16][19] - The goal is to achieve over $1 billion in revenue in 2026, with rare disease expected to account for approximately 60% of total revenues [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the multi-year growth opportunity for Cortrophin, emphasizing the underpenetrated patient populations across various indications [75][76] - The company anticipates significant sequential growth in the second quarter of 2026, driven by the expansion of its sales force and continued performance in its portfolio [62] Other Important Information - ANI ended 2025 with $285.6 million in unrestricted cash, up from $144.9 million at the end of 2024 [55] - The company expects adjusted gross margin to be between 59.3% and 60.3% in 2026, slightly down from 2025 due to higher sales of royalty-bearing products [65] Q&A Session Summary Question: What is the multi-year opportunity for Cortrophin? - Management believes there is significant multi-year growth potential for Cortrophin due to underpenetrated patient populations and ongoing investments in sales and marketing [75][76] Question: How will the royalty structure impact gross margins? - The blended royalty rate for 2026 is anticipated to be in the high 20s, which will affect gross margins moving forward [78] Question: What is the expected operating leverage with the new sales force? - The company expects to maintain EBITDA margin percentages despite the increase in operating expenses related to the sales force expansion [83][84] Question: How is the patient access situation for Cortrophin? - Management has not seen material changes in patient access and continues to target appropriate patients as a late-line therapy [104] Question: What are the expectations for gout utilization in 2026? - Management expects the percentage of volumes from gout to increase significantly with the deployment of the targeted sales force [107][114]

Financial Data and Key Metrics Changes - The company reported total net revenues of $211.4 million for Q2 2025, representing a year-over-year growth of 53% on an as-reported basis and 37% on an organic basis [9][31] - Adjusted non-GAAP EBITDA was $54.1 million, compared to $33.2 million in the prior year period, reflecting strong operational performance [35] - Adjusted non-GAAP EPS was $1.80 for the second quarter, up from $1.02 in the prior year period [34] Business Line Data and Key Metrics Changes - Revenues from the rare disease segment were $104 million, up 111% from the prior year, driven by strong demand for Cortrophin Gel [31][32] - Cortrophin Gel revenues reached $81.6 million, a 66% increase year-over-year, with new patient starts and cases initiated at record highs [9][32] - The retina portfolio, including ILUVIEN and YUTIQ, generated revenues of $22.3 million, consistent with expectations despite ongoing market access challenges [13][32] - The generics business reported revenues of $90.3 million, a 22% increase over the prior year, supported by new product launches [17][32] Market Data and Key Metrics Changes - The ACTH market grew 27% to $684 million in 2024 and is expected to grow 36% to $933 million in 2025, indicating a robust market opportunity [11] - The current number of patients on ACTH therapy is significantly below historical levels, suggesting substantial room for expansion [11][12] Company Strategy and Development Direction - The company is raising its 2025 guidance for total net revenues to between $818 million and $843 million, reflecting strong momentum across both rare disease and generics business units [8][36] - The focus remains on expanding the Cortrophin Gel franchise and addressing market access challenges in the retina segment [12][17] - The company is committed to maintaining a strong presence in the U.S. pharmaceutical industry, with over 90% of revenues coming from domestically manufactured products [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining robust multiyear growth for Cortrophin Gel, driven by increased demand and a growing prescriber base [12][60] - The company anticipates continued challenges in the retina market due to Medicare access issues but remains optimistic about future revenue synergies [17][29] - Management highlighted the importance of ongoing investments in evidence generation and new product presentations to support long-term growth [43][60] Other Important Information - The company ended Q2 with $217.8 million in unrestricted cash, up from $149.8 million at the end of Q1 [35] - The gross margin for Q2 was 64.9%, an increase of over six points from the prior year, driven by a favorable mix towards rare disease products [34][35] Q&A Session Summary Question: Was there anything unusual in Cortrophin's performance? - Management confirmed that the performance was driven by underlying demand, with new patient starts more than doubling in Q2 2025 compared to Q2 2024 [42] Question: What are the priorities for capital use? - The company aims to build cash reserves for reinvestment into the business and potential M&A, with debt paydowns considered in the future [51] Question: How is the payer landscape expected to evolve? - Management indicated that they will continue to engage with payers as they bring Cortrophin therapy to appropriate patients, but specifics were not disclosed [75] Question: What is driving the growth in the ACTH class? - Multiple factors contribute to growth, including increased prescriber adoption, new indications, and the launch of easier-to-use dosage forms [60] Question: How is the prefilled syringe performing? - Seventy percent of new patient starts were with the prefilled syringe, indicating strong adoption across various indications [62] Question: What impact did the New Day trial results have on ILUVIEN? - While the feedback on the New Day study was positive, the expected benefits will be more long-term rather than immediately reflected in guidance [71]